Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences Receives FDA Approval of Integra® Dermal Regeneration Template (IDRT) for Treatment of Chronic Diabetic Foot Ulcers (DFU)
  PLAINSBORO, N.J., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that the United States Food and Drug Administration (FDA) has approved the PMA Supplement for Integra ® Dermal Regeneration Template (IDRT) for the treatment of diabetic
View HTML
Toggle Summary Integra LifeSciences to Host Its Fourth Quarter 2015 Earnings Results Conference Call on February 25, 2016
PLAINSBORO, N.J., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) will release its fourth quarter 2015 financial results on Thursday, February 25, 2016. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results.
View HTML
Toggle Summary Integra LifeSciences Reports Fourth Quarter and Full Year 2015 Financial Results and Issues 2016 Full Year Guidance
Fourth Quarter Revenues Increased 10.1% to $241.2 Million  Fourth Quarter Adjusted EPS of $0.87; Reported EPS of $0.39  Full Year Organic Revenues Increased 6.7% PLAINSBORO, N.J., Feb. 25, 2016 (GLOBE NEWSWIRE) --   Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported its
View HTML
Toggle Summary Integra LifeSciences Announces Service Alliance Agreement With PREZIO Health
PLAINSBORO, N.J., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (NASDAQ:IART) today announced its service alliance agreement with PREZIO Health, a leader in perioperative services, repair, maintenance and management of surgical instruments.
View HTML
Toggle Summary Integra LifeSciences to Present at the Canaccord 11th Annual Musculoskeletal Conference, Raymond James & Associates' 37th Annual Institutional Investors Conference and the Barclays Global Healthcare Conference in March 2016
PLAINSBORO, N.J., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conference in March: At 4:00PM ET on Tuesday, March 1, 2016, Mr. Mark Augusti, President — Orthopedics & Tissue Technologies, will
View HTML
Toggle Summary Integra LifeSciences Awarded $10.3 Million Department of Defense Contract
Medical Technology Products Available Through ECAT System
View HTML
Toggle Summary Integra LifeSciences to Host Its First Quarter 2016 Earnings Results Conference Call on April 27, 2016
PLAINSBORO, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) will release its first quarter 2016 financial results on Wednesday, April 27, 2016. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
View HTML
Toggle Summary Integra LifeSciences Announces Agreement with Vomaris Wound Care, Inc. to Commercialize VolTAC™ Antimicrobial Wound Dressing
Offers Microcurrent Solution for Wound Care Management
View HTML
Toggle Summary Integra LifeSciences Announces Agreement with AlloSource® to Commercialize HuMend™, Human Acellular Dermal Matrix
PLAINSBORO, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, today announced its entry into an agreement with AlloSource ® ,  one of the nation's largest providers of cartilage, cellular, bone, skin and
View HTML
Toggle Summary Integra LifeSciences Announces Initial Clinical Use of the Cadence™ Total Ankle System in the United States
PLAINSBORO, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that the first ten procedures using the Integra® Cadence TM Total Ankle System were successfully completed by Dr.
View HTML
Toggle Summary Integra LifeSciences Provides Update for Omnigraft™ Commercialization Plans, Including Expectations for an Earlier Launch
PLAINSBORO, N.J., April 27, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that the Company is prepared to launch Omnigraft™ Dermal Regeneration Matrix in June 2016, pending receipt of final U.S.
View HTML
Toggle Summary Integra LifeSciences Reports First Quarter 2016 Financial Results
Revenue of $236.8 million; Organic Revenue Increased 8.9%;  Adjusted Net Income Increased 15.3%; Adjusted EPS of $0.74 PLAINSBORO, N.J., April 27, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported its financial results for the first quarter ending
View HTML
Toggle Summary Integra LifeSciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference and the UBS Global Healthcare Conference in May 2016
PLAINSBORO, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conferences in May: At 1:00PM PT on Tuesday, May 10, 2016, Mr. Glenn Coleman, Integra's Chief Financial Officer, will present at the Bank
View HTML
Toggle Summary Integra LifeSciences Receives FDA Approval for Integra® Omnigraft™ Dermal Regeneration Matrix, Clearing the Way for Commercial Release
Launches New Treatment for Hard-to-Heal Diabetic Foot Ulcers
View HTML
Toggle Summary Integra LifeSciences launches Integra® Fin-Lock™ Glenoid for the Titan™ Modular Shoulder System
PLAINSBORO, N.J., May 23, 2016 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation   (Nasdaq:IART), a leading global medical technology company, today announced the launch of the Integra® Fin-Lock™ Glenoid. This addition to the Titan™ Modular Shoulder System increases the glenoid
View HTML